Milk-Derived Extracellular Vesicles: A Novel Perspective on Comparative Therapeutics and Targeted Nanocarrier Application DOI Creative Commons
Muttiah Barathan, Sook Luan Ng, Yogeswaran Lokanathan

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1282 - 1282

Published: Nov. 15, 2024

Milk-derived extracellular vesicles (mEVs) are emerging as promising therapeutic candidates due to their unique properties and versatile functions. These play a crucial role in immunomodulation by influencing macrophage differentiation cytokine production, potentially aiding the treatment of conditions such bone loss, fibrosis, cancer. mEVs also have capacity modulate gut microbiota composition, which may alleviate symptoms inflammatory bowel diseases promote intestinal barrier integrity. Their potential drug delivery vehicles is significant, enhancing stability, solubility, bioavailability anticancer agents while supporting wound healing reducing inflammation. Additionally, bovine exhibit anti-aging protect skin cells from UV damage. As vaccine platforms, offer advantages including biocompatibility, antigen protection, ability elicit robust immune responses through targeted specific cells. Despite these applications, challenges persist, complex roles cancer, effective loading, regulatory hurdles, need for standardized production methods. Achieving high targeting specificity understanding long-term effects mEV-based therapies essential clinical translation. Ongoing research aims optimize mEV methods, enhance capabilities, conduct rigorous preclinical studies. By addressing challenges, hold revolutionize development delivery, ultimately improving outcomes across various medical fields.

Language: Английский

Goat Milk-Derived Extracellular Vesicles Alleviate Colitis Potentially Through Improved Gut Microbiota in Mice DOI Creative Commons
Xinru Wang, Yi Liu, Chang Hong

et al.

Foods, Journal Year: 2025, Volume and Issue: 14(9), P. 1514 - 1514

Published: April 26, 2025

Ulcerative colitis (UC) is characterized clinically by intestinal inflammation and gut microbiota dysbiosis. The consumption of biologics, although effective in control, may lead to adverse effects inconvenient for at-home administration. Goat milk-derived extracellular vesicles (GMEVs) have been proposed as a supplement prevent inflammation. However, their therapeutic potential remains elusive. This study aimed explore the preventive effect GMEVs on its underlying mechanisms through microbiota-immune axis using dextran sodium sulfate (DSS)-induced mouse model. We found that pre-treatment 20 mg/kg/d effectively prevented body weight loss, colon shortening, depletion colonic goblet cells, disappearance crypts, while enhancing mucosal barrier. Consistent with these phenotypes, GMEV increased levels IL-22 IL-10 decreased IL-1β, TNF-α, IL-6, iNOS. themselves had no normal mice. Paralleling alleviation inflammation, also restored reduction unclassified Muribaculaceae, Dubosiella, Lactobacillus suppressed expansion Alistipes Proteobacteria following DSS treatment. Additionally, intake significantly downregulated expression proteins NF-κB signaling pathway induced DSS. In summary, could regulating barrier, microbiota, organ damage, immune microenvironment. demonstrated application prospects UC prevention.

Language: Английский

Citations

0
Milk-Derived Extracellular Vesicles: A Novel Perspective on Comparative Therapeutics and Targeted Nanocarrier Application DOI Creative Commons
Muttiah Barathan, Sook Luan Ng, Yogeswaran Lokanathan

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(11), P. 1282 - 1282

Published: Nov. 15, 2024

Milk-derived extracellular vesicles (mEVs) are emerging as promising therapeutic candidates due to their unique properties and versatile functions. These play a crucial role in immunomodulation by influencing macrophage differentiation cytokine production, potentially aiding the treatment of conditions such bone loss, fibrosis, cancer. mEVs also have capacity modulate gut microbiota composition, which may alleviate symptoms inflammatory bowel diseases promote intestinal barrier integrity. Their potential drug delivery vehicles is significant, enhancing stability, solubility, bioavailability anticancer agents while supporting wound healing reducing inflammation. Additionally, bovine exhibit anti-aging protect skin cells from UV damage. As vaccine platforms, offer advantages including biocompatibility, antigen protection, ability elicit robust immune responses through targeted specific cells. Despite these applications, challenges persist, complex roles cancer, effective loading, regulatory hurdles, need for standardized production methods. Achieving high targeting specificity understanding long-term effects mEV-based therapies essential clinical translation. Ongoing research aims optimize mEV methods, enhance capabilities, conduct rigorous preclinical studies. By addressing challenges, hold revolutionize development delivery, ultimately improving outcomes across various medical fields.

Language: Английский

Citations

1